ClinicalTrials.gg
RecruitingNCT02156401VTEvalUpdated Jun 17, 2024

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

An observational study in Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), sponsored by Johannes Gutenberg University Mainz. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-17.

Sponsored by Johannes Gutenberg University Mainz · Observational

How we know

From the registry’s dates

  • Started Apr 2013; still recruiting 13 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Venous Thromboembolism with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Venous Thromboembolism · Germany.

Planned enrollment
14th of 25
2,000 · median 2,318
Started
2013
with 1 other
Observational
25 of 61
3 open now
Registered
35th of 61
by date
Lead sponsor
2 of 61
Johannes Gutenberg University Mainz

Among the 61 studies in Venous Thromboembolism with a site in Germany, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2013, is one of 25 observational ones, and was the 35th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

4 of the 61 studies in Venous Thromboembolism with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Venous Thromboembolism with a site in Germany, or all of them as a file.
02

Study summary

Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.

VTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).

The standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.

03

Conditions studied

  • Venous Thromboembolism (VTE)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)

Keywords

  • Venous thromboembolism
  • Deep vein thrombosis
  • Pulmonary embolism
  • Cohort study/epidemiology
  • Outcome
  • Prognosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Individuals either with clinically suspected or incident diagnosis of VTE

Eligibility criteria

Inclusion Criteria:

  • Age ≥18 years and Informed written consent
  • Clinical condition:

    • Cohort 1: Clinical suspicion of acute PE (with or without DVT)
    • Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)
    • Cohort 3: Incidentally diagnosed VTE
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 1: Suspect of Pulmonary Embolism (PE)
  • Cohort 2: Suspect of Deep Vein Thrombosis (DVT)
  • Cohort 3: Incidental Venous Thromboembolism (VTE)
06

What researchers measure

Primary outcomes

  1. Mortality

    Overall mortality, consisting of: * PE-related death * All other causes of death

    Time frame: Baseline

  2. Symptomatic venous thromboembolism

    Composed by: * PE-related death * Development or recurrence of nonfatal PE * Development or recurrence of DVT

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

Secondary outcomes

  1. Hemodynamic instability

    Defined as at least one of the following: * Cardiopulmonary resuscitation (CPR) or defibrillation * Cardiogenic shock or need of catecholamine administration * Systolic blood pressure \< 90mm Hg, or a pressure drop by more than 40mm Hg for \>15 min

    Time frame: Baseline

  2. Use of mechanical ventilation

    Time frame: Baseline

  3. Admission to Intensive Care Unit (ICU)

    Time frame: Baseline

  4. Recurrence of acute PE

    Time frame: Baseline

  5. Cardiac dysfunction or heart failure

    Time frame: Baseline

  6. Pneumonia

    Time frame: Baseline

  7. Symptomatic and/or asymptomatic DVT

    Time frame: Baseline

  8. Major bleeding

    Time frame: Baseline

  9. Clinically relevant non-major bleedings

    Time frame: Baseline

  10. Diagnostic of a previously unknown malignancy

    Time frame: Baseline

  11. Length of hospitalization

    Time frame: Baseline

  12. Implantation of vena cava filter

    Time frame: Baseline

  13. Thrombolytic treatment

    Time frame: Baseline

  14. Interventional treatment

    Time frame: Baseline

  15. Surgery

    Time frame: Baseline

  16. Overall mortality

    Time frame: Assessment at month 3/6 and 12; year 2-6 (Active follow-up)

  17. PE-related death

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  18. Development or recurrence of clinical symptomatic PE/DVT

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  19. Asymptomatic DVT

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  20. Chronic venous insufficiency (CVI)

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  21. Post-thrombotic Syndrome (PTS)

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  22. Development of cardiac dysfunction or heart failure

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  23. Development of pulmonary hypertension

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  24. Respiratory dysfunction

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  25. Major bleeding

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  26. Clinically relevant non-major bleedings

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  27. Diagnostic of a previously unknown malignancy

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  28. Net clinical outcome (NCO)

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  29. O2 home treatment

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  30. Pulmonary vasoactive drugs

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  31. Development of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  32. Hospitalization

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  33. Length of stay in Hospital due to VTE

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  34. Major adverse cardiac and cerebrovascular event (MACCE)

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  35. Cardiovascular event

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

  36. Cerebrovascular event

    Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)

07

Study locations

1 of 1 sites recruiting
  • University Medical Center of the Johannes Gutenberg University Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
    • Philipp S Wild, MD, MSc · Contactphilipp.wild@unimedizin-mainz.de · 00496131177163
    • Philipp S Wild, MD, MSc · Principal investigator
    • Stavros Konstantinides, MD, FESC · Principal investigator
08

References and documents

Publications

  • Ten Cate V, Eggebrecht L, Schulz A, Panova-Noeva M, Lenz M, Koeck T, Rapp S, Arnold N, Lackner KJ, Konstantinides S, Espinola-Klein C, Munzel T, Prochaska JH, Wild PS. Isolated Pulmonary Embolism Is Associated With a High Risk of Arterial Thrombotic Disease: Results From the VTEval Study. Chest. 2020 Jul;158(1):341-349. doi: 10.1016/j.chest.2020.01.055. Epub 2020 Mar 23. PubMed 32217063 ↗
  • Frank B, Ariza L, Lamparter H, Grossmann V, Prochaska JH, Ullmann A, Kindler F, Weisser G, Walter U, Lackner KJ, Espinola-Klein C, Munzel T, Konstantinides SV, Wild PS; VTEval study group. Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project. BMJ Open. 2015 Jul 1;5(7):e008157. doi: 10.1136/bmjopen-2015-008157. PubMed 26133379 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2013 (actual). Primary completion is estimated for Jul 2030, 207 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 207 months is above that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
Jun 5, 2014
StartActual
Apr 2013
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Jun 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02156401
Collaborators
Maastricht University, Hochschule Fresenius, University of Bonn, Siemens Corporation, Corporate Technology, Bayer, Eurofins
Responsible party
Philipp Wild, MD, MSc (Univ.-Prof. Dr. med. Philipp Wild, MSc, Johannes Gutenberg University Mainz) — Principal investigator
First posted
Jun 5, 2014
Start date
Apr 2013
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Jun 17, 2024

Study contacts

Philipp S Wild, MD, MSc
Contact
philipp.wild@unimedizin-mainz.de
0049 6131 17 7163
Philipp S Wild, MD, MSc
principal investigator · University Medical Center of Johannes Gutenberg University Mainz, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion